- Processing Solutions
- Agitators
- Asset Management
- Automation
- Blowers & Fans
- Centrifuges
- Chillers
- Compressors
- Conveyors
- Dryers & Evaporators
- Feeders
- Filtration & Separation
- Flowmeters
- Fluid Flow
- Heat Exchangers
- Instrumentation
- Level Measurement
- Maintenance & Safety
- Mixing & Blending
- Motors & Drives
- Oil Skimmers
- Piping & Tubing
- Packaging Equipment
- Powder & Bulk Solids
- Process Control
- Pumps & Seals
- Size Reduction
- Tanks & Vessels
- Valves & Actuators
- Weighing
- More
- Newsletters
- White Papers
- Buyer's Guide
- Videos
- Events
- Advertise
Drug developer Schering-Plough Corp. is seeking marketing approval from the Food and Drug Administration for a tablet used to treat schizophrenia and bipolar disorder, the Associated Press reports. Schering-Plough said the FDA accepted the new drug application of asenapine for a standard review. Schering-Plough acquired asenapine through its buyout of Organon BioSciences NV earlier this month. The clinical trial program for the drug has so far consisted of schizophrenia.
More